Innovative tests for
cancer patient monitoring

Discover our new M*Detect product for digital PCR !

MDetect kits from METHYS Dx are based on proprietary methylation signatures and are compatible with commercially available digital PCR instruments. MDetect kits are used to analyze circulating tumor DNA from patients with advanced cancers (stages III–IV). Thanks to the use of digital PCR, results can be obtained within a single day.

Prélèvement dans une éprouvette

Based on
methylated dna biomarkers

Our tests are based on liquid biopsies, and target the analysis of certain types of biomarkers, present in biological fluids, such as blood. METHYS Dx develops panels of methylation markers, in order to characterize circulating tumor DNA (ctDNA) within liquid biopsies. The tests developped by METHYS Dx will thus be used to establish prognosis, monitor tumor evolution, and allow the early detection of relapses.

The tests developped by METHYS Dx target different cancer types, amongst the most frequent. These tests are based on a novel detection technology, and present an efficient and less-costly alternative to NGS tests. METHYS Dx tests can also be used for quality control of results obtained using other technologies (NGS or digital PCR for example).

METHYS Dx

Our values

Scientifique dans son laboratoire
Innovation

Innovation

Précision

Precision & Reliability

Bienveillance

Passion

news

04Feb World cancer day

Today marks World Cancer Day, an important moment to raise awareness, reflect, and reaffirm our collective commitment to fighting cancer. This day is a reminder of the importance of research, innovation and collaboration to improve prevention, diagnosis, patient follow-up and care. At Methys Dx, we remain committed to contributing to these efforts through our work […]

> Know more
01Dec METHYS Dx Expands Access to its M*Detect kits for digital PCR Across Europe and North America with Distribution Agreement with CliniSciences

Paris, 01/12/2025. METHYS Dx, a company with pioneering liquid biopsy solutions based on methylation signatures, announced today it had entered into a distribution agreement with CliniSciences. This agreement will enable the large-scale commercialization of METHYS Dx M*Detect kits for digital PCR in RUO (Research Use Only) format across Europe, North America and North Africa. METHYS […]

> Know more